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Objective: The 20-year data from the ongoing long-term study of the St Jude Medical Biocor (St Jude Medical,
St Paul, Minn) porcine bioprosthesis are reported. Earlier follow-ups have shown that the valve has excellent
durability. After 20 years, will this continue to be true?
Methods: Data were obtained for 1712 patients who underwent valve replacement (1518 aortic valve replace-
ments; 194 mitral valve replacements) with glutaraldehyde-preserved Biocor bioprostheses at Sahlgrenska Uni-
versity Hospital (Sweden) between 1983 and 2003. Follow-up after surgery was evaluated on alternate years
using hospital records, interviews, and questionnaires.
Results: At 20 years, the cumulative follow-up was 8843 and 1195 patient-years for aortic valve replacement and
mitral valve replacement, respectively. Survival after aortic valve replacement was 17.7% 3.3%, and survival
after mitral valve replacement was 16.4%  4.7%. Actuarial freedom from reoperation because of structural
valve deterioration was 61.1%  8.5% and 79.3%  6.0% after aortic valve replacement and mitral valve re-
placement, respectively. (The equivalent actual/cumulative values were 85.6% 2.2% and 91.2% 2.6%, re-
spectively.) In aortic valve recipients aged 65 years or less and more than 65 years, actuarial freedom from
reoperation because of structural valve deterioration was 44.5%  9.2% and 92.1%  3.9%, respectively.
The equivalent values in mitral valve recipients were 75.2%  7.6% and 88.0%  8.1%, respectively.
Conclusion: The 20-year data confirm the excellent valve durability reported at the 17-year follow-up after both
aortic valve replacement and mitral valve replacement using the Biocor porcine bioprosthesis.Close to 40 years after the introduction of bioprosthetic car-
diac valves, prosthesis selection remains complex and must
take into account each patient’s individual needs. The first
choice facing a cardiac surgeon is whether to use a mechan-
ical valve—requiring the patient to undergo lifelong antico-
agulant therapy with a subsequent risk of bleeding
complications—or a bioprosthetic valve, with its potential
risk of reoperation within 10 to 15 years because of tissue
failure.1 Patients aged more than 65 years have a relatively
low risk of calcification and valve failure, which minimizes
the risk of reoperation during their lifetime, and so are in-
creasingly receiving bioprosthetic valves.1 Mechanical
valves are widely used for patients aged less than 65 years,
although long-term anticoagulant use remains a concern.1
This has become enough of an issue in recent years that it
is now more common to use bioprostheses in younger pa-
tients. It is impossible to predict whether this development
will improve patient outcomes.
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complicated, by emerging data from long-term studies of
both porcine and pericardial valves.2-4 These studies are yield-
ing much-needed information on valve durability, which
should be the primary consideration for most patients.2-4
Previous publications on the Biocor porcine prosthesis (St
Jude Medical, St Paul, Minn) have demonstrated that it per-
forms well and has good durability for up to 17 years after im-
plantation.5-10 This article reports outcomes at the 20-year
follow-up from an ongoing long-term prospective study.5-8
MATERIALS AND METHODS
The design and methods of this study have been outlined in previous
publications.5-8
Patients
This report includes data on consecutive patients who underwent either
aortic valve replacement (AVR) (n ¼ 1518) or mitral valve replacement
(MVR) (n¼ 194) at Sahlgrenska University Hospital, Gothenburg, Sweden,
between January of 1983 and January of 2003. Informed consent was ob-
tained from each study participant. All patients in this study received a Biocor
bioprosthesis preserved in glutaraldehyde at low pressure, none of which had
been ‘‘No-React’’ treated. The Biocor valve was the only bioprosthesis used
at the Sahlgrenska University Hospital during this period of time. Approxi-
mately 30% of our patients undergoing cardiac valve replacement received
a bioprosthesis and 70% received mechanical valves during the study pe-
riod. Baseline patient characteristics are shown in Table 1.
Surgical Procedures
Operative procedures, prophylactic antibiotic therapy, and anticoagula-
tion were standardized as described previously.5-8 Patients received antico-
agulation with warfarin for 3 months from the second day after surgery withery c January 2009
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AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
MVR ¼ mitral valve replacement
SVD ¼ structural valve deterioration
the goal of maintaining the international normalized ratio value between 2.0
and 3.0.
Follow-up
Patients received follow-up questionnaires, and additional phone calls if
needed, on alternate years from the time of their operation. Data were col-
lected from medical charts (including all data for any suspected complica-
tion), autopsy reports (obtained for 50% of all deaths), or death
certificates.
Data Analysis
Patient data were assessed and valve-related complications were defined
according to The Society of Thoracic Surgeons and American Association
for Thoracic Surgery Guidelines (1996 revision).11 Only actuarial data have
been used to plot figures, in line with published guidance.12 At 20-year
follow-up, we also used linearized event rates to represent the number of
complications per 100 patient-years.
RESULTS
The follow-up was 99.9% complete, and the cumulative
follow-up times were 8843 and 1195 patient-years for
AVR and MVR, respectively. The mean follow-up times
were 6.0 4.5 years for AVR and 6.2 5.6 years for MVR.
Patient Survival
Early mortality. Seventy-seven patients undergoing AVR
and 25 patients undergoing MVR died while in hospital
postoperatively or within 30 days if the patient was dis-
charged from hospital. None of these early deaths can be re-
garded as valve-related.
Late mortality. There were 541 deaths in the AVR group
and 93 deaths in the MVR group. Causes of late death are
shown in Table 2.
The overall survival was 17.7%  3.3% after AVR and
16.4%  4.7% after MVR. Additional coronary artery by-
pass grafting (CABG) was linked to impaired survival com-
pared with isolated valve replacement: Survival was 4.6%
3.8% after AVR plus CABG versus 22.3%  4.1% after
isolated AVR, whereas survival was 15.5%  7.1% after
MVR plus CABG compared with 21.6%  5.3% after iso-
lated MVR.
There were 58 valve-related deaths (46 AVR recipients,
12 MVR recipients), as seen in Table 2. This corresponded
to an incidence of 0.5%/patient-years and 1.0%/patient-
years for patients undergoing AVR and MVR, respectively.
The rates of actuarial freedom from valve-related death
were 84.3%  6.9% and 88.0%  4.0% for AVR andThe Journal of Thoracic andMVR recipients, respectively, as shown in Figure 1.
Actual/cumulative freedom from valve-related death was
92.5%  1.8% and 92.8%  2.2% for AVR and MVR
recipients, respectively.
Functional Class
At the 20-year follow-up, 50%, 28%, 20%, and 2% of
patients who underwent AVR were in New York Heart As-
sociation functional class I, II, III, and IV, respectively, com-
pared with 34%, 36%, 29%, and 2% of patients who
underwent MVR.
Complications
Complication incidences per patient-year over 20 years’
follow-up are summarized in Table 3.
Reoperations. A total of 146 patients required reoperation
within the study period. The most common cause of reoper-
ation was structural valve deterioration (SVD), which led to
reoperation for 77 patients undergoing AVR and 11 patients
undergoing MVR. The incidence of reoperation was 0.9%
per patient-year in each valve position. Valve deterioration
was due to stenosis in 10%, insufficiency in 25%, mixed
stenosis and insufficiency in 51%, and ‘‘no visual damage’’
in 14% of cases.
Actuarial freedom from reoperation because of SVD was
61.1%  8.5% and 79.3%  6.0% after AVR and MVR,
respectively (Figure 2). (The equivalent actual values were
TABLE 1. Patient demographics at baselines
AVR MVR
N 1518 194
Male/female 964/554 95/99
Age (y)
Mean 70.8  10.9 64.9  12.3
Median 74 68
Range 16–88 22–83
Concomitant CABG 632 (42%) 65 (34%)
Previous cardiac operations 54 (4%) 32 (16%)
Active infective endocarditis 41 (3%) 13 (7%)
Diagnosis
Aortic insufficiency 188
Aortic stenosis 1116
Mixed 214
Mitral insufficiency 133
Mitral stenosis 32
Mixed 29
NYHA classification
I 122 2
II 381 20
III 855 128
IV 129 44
Data missing 31 0
AVR, Aortic valve replacement; MVR, mitral valve replacement; CABG, coronary
artery bypass grafting; NYHA, New York Heart Association.Cardiovascular Surgery c Volume 137, Number 1 77
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freedom from reoperation because of SVD according to
age group is shown in Table 4; Figure 3 compares freedom
from reoperation because of SVD over time in patients
aged more than 65 years and patients aged 65 years or less.
There was no early mortality at reoperation for SVD. A fur-
ther 33 patients required reoperation for prosthetic valve en-
docarditis (see below), and another 27 patients required
reoperation for nonstructural valve dysfunction (mainly par-
avalvular leak).
Thromboembolic and anticoagulant-related events. Ac-
tuarial freedom from thromboembolism at follow-up was
70.8%  5.5% and 71.3%  5.7% after AVR and MVR,
respectively. (The equivalent actual values were 84.1% 
1.7% and 82.9% 3.2%, respectively.) Of the patients un-
dergoing AVR, those aged less than 50 years when they re-
ceived their replacement valve in the aortic position had the
highest actuarial freedom from thromboembolic events:
98.8%  1.2%; the equivalent values for patients aged 65
years or less and patients aged more than 65 years were
87.5%  3.8% and 34.4%  2.5%, respectively.
Actuarial freedom from anticoagulant-related hemorrhage
was 83.1%  6.8% and 85.8%  4.3% after AVR or
MVR, respectively. (The corresponding actual figures
were 91.3%  1.8% and 91.7%  2.3%, respectively.)
At follow-up, 8% of the patients undergoing AVR and
40% of the patients undergoing MVR were receiving anti-
coagulation.
TABLE 2. Causes of late mortality
AVR MVR
SVD 3 1
TE 21 3
ACH 14 4
PVE 8 4
Other cardiac 234 47
Noncardiac 247 32
AVR, Aortic valve replacement; MVR, mitral valve replacement; SVD, structural valve
deterioration; TE, thromboembolic event; ACH, anticoagulant-related hemorrhage;
PVE, prosthetic valve endocarditis.
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FIGURE 1. Actuarial freedom from valve-related death (according to valve
position). AVR, Aortic valve replacement; MVR, mitral valve replacement.78 The Journal of Thoracic and Cardiovascular SurgProsthetic valve endocarditis. Actuarial freedom from
prosthetic valve endocarditis was 95.1% 1.5% at 20 years
after AVR and 91.7%  3.1% after MVR. (Corresponding
actual values were 97.3%  0.6% and 94.6%  1.8%,
respectively.)
Doppler Echocardiography
Doppler echocardiography can be useful for providing
a complete picture of patient outcomes after valve replace-
ment surgery, so we aimed to collect as much long-term
postoperative echocardiography data as possible and contin-
ued until 2007. Availability is limited, however, especially
for the many elderly patients who are resident in nursing
homes. There is a wide variation in the completeness of in-
vestigations achieved, but all echocardiograms of prosthetic
aortic valves include a peak gradient value.
Echocardiography data are available for 1003 AVR recip-
ients: 57%with 5 years’ follow-up, 27%with 5 to 10 years’
follow-up, and 16% with more than 10 years’ follow-up.
Less than 1 in 10 patients (76/1003; 7.5%) had peak gradient
values greater than 60 mm Hg, suggesting a gradual valve
deterioration. The remaining 927 patients had a mean peak
gradient of 30.6  10.9 mm Hg (all valve sizes included).
DISCUSSION
This article reports data from more than 10,000 patient-
years of follow-up over 20 years in approximately 1800
TABLE 3. Complication incidences per patient-year
No. Incidence/patient-year (%)
Reoperation because of SVD AVR 78 0.9
MVR 11 0.9
Reoperation because of PVE AVR 24 0.3
MVR 9 0.7
ACH AVR 77 0.9
MVR 13 1.0
TE AVR 139 1.6
MVR 26 2.2
SVD, Structural valve deterioration; AVR, aortic valve replacement; MVR, mitral valve
replacement; PVE, prosthetic valve endocarditis; ACH, anticoagulant-related hemor-
rhage; TE, thromboembolic event.
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FIGURE 2. Actuarial freedom from reoperation because of SVD (accord-
ing to valve position). AVR, Aortic valve replacement; MVR, mitral valve
replacement; SVD, structural valve deterioration.ery c January 2009
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sistent with previously published outcomes of the same
study at 10-, 15-, and 17-year follow-ups.5-8 This is one of
the largest published studies of outcomes after bioprosthetic
valve replacement to date. Results of such long-term studies
have started to emerge in recent years, but evidence of the
long-term durability of currently available prosthetic valves
is still limited.1-4,8 There remain few published studies with
sufficiently prolonged follow-up to enable direct compari-
son between the St Jude Medical Biocor porcine bioprosthe-
sis and other bioprostheses. Even articles such as Jamieson
and colleagues’ 2005 long-term follow-up2 on the Carpent-
ier-Edwards (Edwards Lifesciences, Irvine, Calif) supra-
annular aortic porcine bioprosthesis reported most outcomes
at 15- and 18-year follow-ups. Thus, more data from robust
large-scale studies are required to make the best choice of
prosthetic valve for each individual patient.
It is also relevant to note that it is difficult to compare out-
comes in populations with differing baseline characteristics,
and different study reports rarely include all of the same base-
line characteristics.13 Our results compare well, however,
with the few available 20-year publications on bioprosthetic
heart valves (key outcomes are summarized in Table 5).
Long-term Survival after Valve Replacement
Survival in our study was 17.7  3.3 for AVR recipients
and 16.4  4.7 for MVR recipients, which compares favor-
ably with or is comparable to the overall 19-year survival for
single bioprosthetic valve replacements according to the
United Kingdom Heart Valve Registry Report 2003
(19.92%; 95% confidence interval, 18.54–21.34%).14 It
should be noted that it is difficult to compare survival across
different patient groups and countries because of the base-
line and population differences, as well as other factors
that can affect outcomes in valve-replacement recipients,
such as the degree of hypertrophy at the time of operation
or postoperative hypertension.15
Survival over 20 years in Biocor recipients compares well
with the few available 20-year publications on bioprosthetic
heart valves. The 20-year follow-up study on the Carpentier-
Edwards supra-annular aortic porcine bioprosthesis reported
a survival of 6.8%  2.0%, compared with our observed
survival of 17.7%  3.3% in aortic Biocor recipients.2
There is no clear explanation for the apparent difference in
TABLE 4. Actuarial freedom from reoperation because of structural
valve deterioration according to age group
Age groups Aortic valve replacement Mitral valve replacement
50 y 37.7%  8.6% 57.6%  1.5%
51–60 y 60.7%  10.3% 80.0%  1.9%
61–70 y 81.0%  5.1% 86.3%  0.7%
71–80 y 97.8%  1.2% 100% (>70 y)
>80 y 100% 100% (>70 y)The Journal of Thoracic andsurvival with Biocor versus the Carpentier-Edwards supra-
annular valve, because reported patient characteristics such
as age (slightly higher in our group) and baseline coronary
artery disease/CABG are similar in both study populations.2
The study of 20-year outcomes using the Hancock II por-
cine bioprosthesis (Medtronic, Minneapolis, Minn) reported
overall survival similar to our study (19%  4%).4 Borger
and coworkers4 also reported a 20-year survival of 6% 
3% in 559 mitral valve recipients,4 compared with our ob-
served survival of 16.4%  4.7% in 194 patients, although
these data should be interpreted with caution because of the
small patient numbers.
Long-term Durability
The most important quality of a bioprosthesis is durabil-
ity, and long-term clinical studies are essential for evaluating
this.13 It is impossible to be sure that a device performing
well in preclinical animal studies will continue to do so in
the long term when implanted in humans, as illustrated by
the failure of the sheep model to reveal a design flaw that
led to leaflet abrasion in subsequent clinical trials.16,17 Fol-
low-up of less than 15 years has limited value in assessing
bioprosthesis durability, and at least 15 to 20 years’ fol-
low-up is required.13
The actuarial freedom from SVD in aortic valve recipi-
ents at 18 years in the 20-year Carpentier-Edwards supra-
annular valve study was 64%  4% (with a corresponding
actual value of 86%  1%), which is comparable to our
current 20-year actuarial freedom from reoperation be-
cause of SVD of 61.1%  8.5% (and actual freedom of
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FIGURE 3. Actuarial freedom from reoperation because of SVD accord-
ing to age in (A) AVR recipients and (B) MVR recipients. AVR,Aortic valve
replacement; MVR, mitral valve replacement; SVD, structural valve deteri-
oration.Cardiovascular Surgery c Volume 137, Number 1 79
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valve replacement
Follow-up time Bioprosthesis, reference Mean age
Actuarial
survival
Actuarial freedom
from valve-related
death
Actuarial freedom
from reoperation
because of SVD
20 y St Jude Medical Biocor porcine
bioprosthesis (St Jude Medical,
St Paul, Minn), current study
70.8  10.9 y 17.7%  3.3% 84.3%  6.9% Overall: 61.1%  8.5%
Age<65 y: 44.5%  9.2%
Age  65 y: 92.1%  3.9%
Carpentier-Edwards SAV porcine
bioprosthesis (Edwards
Lifesciences, Irvine, Calif),
Jamieson and colleagues2
68.8  10.9 y 6.8%  2.0% Not reported Not reported
Hancock II porcine bioprosthesis,
Borger and colleagues4
67  11 y 19%  4% Not reported Overall: Not reported
Age<65 y: 39%  9%
Age  65 y: 73%  16%
Carpentier-Edwards Perimount
pericardial bioprosthesis,
clinical communication22
64.9  12 y Not reported 67.9%  6.6% Overall: Not reported
Age  65 y: 81.5%  9.6%
Age>70 y: 69.9%  20.5%
18 y Carpentier-Edwards SAV porcine
bioprosthesis, Jamieson and
colleagues2
68.8  10.9 y 15.8%  1.6% 78.4%  2.9% (Reported as freedom from SVD)
Overall: 64.0%  3.6%
Age  50 y: 31.9%  6.3%
Age 51–60: 51.0%  7.0%
Age 61–70 y: 77.6%  4.9%
Age>70 y: 94.6%  2.3%
Carpentier-Edwards Perimount
pericardial bioprosthesis,
Aupart and colleagues18
72.6 y 22%  4% 82%  3% 68%  12%
17 y St Jude Medical Biocor porcine
bioprosthesis, Myke´n8
70.8  10.9 y 28.2%  3.7% 89.9%  3.0% 73.9%  4.1%
Mitroflow pericardial
bioprosthesis, Yankah
and colleagues3
72.4  8.4 y 23.2%  2% 92.0%  2.2% 67.0%  4.9%
SVD, Structural valve deterioration; SAV, supra-annular aortic valve.85.6% 2.2%) after implantation of the Biocor valve in the
aortic position.2 As reported previously, actuarial freedom
from reoperation because of SVD was 73.9%  4.1% at
17 years after AVR using the Biocor bioprosthesis.2,8
Borger and coworkers’4 report of 20-year outcomes using
the Hancock II porcine bioprosthesis includes data on 1010
aortic valve recipients with a mean age of 67 years. This
study reports actuarial freedom from reoperation for SVD
in AVR of 39%  9% for patients aged less than 65 years
and 73% 16% for patients aged 65 years or more. Our re-
sults for the same period of time are 44.5%  9.2% (65
years) and 92.1%  3.9% (>65 years), which are superior,
particularly in those aged more than 65 years. This result in
patients aged more than 65 years at 20 years’ follow-up also
compares favorably with a result of 85%  8% from an
18-year study on the Carpentier-Edwards Perimount bio-
prosthesis (Edwards Lifesciences) in the aortic position.18
Indeed, our reported freedom from SVD after implanta-
tion of the Biocor valve compares well with 14-year19 and
15-year20 follow-up data using alternative bioprostheses.
Marchand and colleagues19 reported 69%  5% actuarial
freedom from SVD in all patients (mean age 61 years)80 The Journal of Thoracic and Cardiovascular Surgover 14 years with the Carpentier-Edwards Perimount valve
in the mitral position, whereas a value of 79.3%  6.0%
(mean age 65 years) was obtained in our study with the Bio-
cor bioprosthesis. David and colleagues20 reported a 15-year
actual freedom from SVD of 89% 4% in MVR recipients
of the Hancock II bioprosthesis aged more than 65 years; this
age group’s actual freedom from SVD was 97%  2% in
our study, which had a longer follow-up. In patients aged
less than 65 years with the valve in the mitral position, David
and colleagues reported actual freedom from SVD to be
76%  5% at 15 years’ follow-up, compared with our ac-
tual freedom from SVD of 85%  4% over a longer period
of time.
According to all long-term follow-ups, SVD occurs
earlier in the mitral position than in the aortic position. How-
ever, the Biocor porcine bioprosthesis has previously shown
comparable durability in both mitral and aortic positions.8,7
Borger and coworkers4 reported 20-year actuarial freedom
from SVD with Hancock II mitral valves of 27%  9%
and 59%  11% in patients aged less than and more than
65 years, respectively. The actuarial freedom from SVD in
our study of 75.2%  7.6% and 88.0%  8.1% in theery c January 2009
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ference in favor of the Biocor valve.
Minami and colleagues21 reported the 19-year results for
the Mitroflow Synergy pericardial valve (Sorin Group Can-
ada Inc, Burnaby, BC, Canada) (n ¼ 1516). The results for
actuarial freedom from endocarditis, tear, and valve degen-
eration showed that implantations should be restricted to
patients aged more than 75 years, whereas the Biocor
bioprosthesis has shown good durability over the same
time scale in patients aged more than 65 years.
Long-term Complications
Complications using the Biocor valve also compared fa-
vorably with alternative bioprostheses. Our observed actuar-
ial freedom from thromboembolism after AVR (70.8% 
5.5%) was comparable to that from the 20-year results using
the Hancock II bioprosthesis (79%  3%) and 18-year
results using the Carpentier-Edwards supra-annular valve
(66.0%  5.1%).2,4 The fact that our results range from
98.8% 1.2% in patients aged less than 50 years at implan-
tation to 34.4% 2.5% in patients aged more than 65 years
suggests that the frequency of thromboembolic events may
be associated more with age than valve.
Actuarial freedom from prosthetic valve endocarditis at
20 years with the Hancock II valve was 91%  5% in
AVR recipients and 85  5% in MVR recipients,4 com-
pared with 95.1%  1.5% (AVR) and 91.7%  3.0%
(MVR) with the Biocor bioprosthesis. Similarly, Jamieson
and coworkers2 reported actuarial freedom from prosthetic
valve endocarditis of 92%  2% (and an actual value of
97% 1%) at 18 years’ follow-up using the Carpentier-Ed-
wards supra-annular valve for AVR, which is more or less
identical to our result of 95.1%  1.5% (actual: 97.3% 
0.6%). Actuarial freedom from anticoagulant-related hem-
orrhage was 89%  2% (actual: 94%  1%) at 18 years
in the same study; our value of 83.1%  6.8% (actual:
91.3%  1.8%) at 20 years is similar (Borger and col-
leagues4 did not report freedom from anticoagulant-related
hemorrhage).2
CONCLUSIONS
This study provides some of the most robust evidence
available on long-term outcomes after bioprosthetic heart
valve replacement. Long-term durability is the most impor-
tant parameter when evaluating bioprosthesis, and these re-
sults clearly demonstrate the excellent durability of the St
Jude Medical Biocor porcine bioprosthesis over 20 years
in both aortic and mitral positions. These data are consistent
with previous reports at 10-, 15-, and 17-years’ follow-up
using the Biocor valve and provide a valuable addition to
the limited number of long-term study reports that have
been published to date.The Journal of Thoracic andReferences
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